Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CTSV | O60911 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614590 | 0.91 | CTSV (0.39) | APPMAPTKMT2AMEN1CTSV | |
| SCHEMBL6080661 | 0.90 | APP (0.43) | APPMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6079883 | 0.89 | MMP2 (0.41) | MAPTSMN1; SMN2KMT2AMEN1MMP2 | |
| SCHEMBL6079222 | 0.87 | APP (0.41) | APPMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6080214 | 0.87 | APP (0.43) | APPMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6080358 | 0.86 | CYP11B1 (0.43) | APPMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6080282 | 0.83 | CTSV (0.39) | APPMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6079326 | 0.82 | APP (0.45) | APPMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6079319 | 0.82 | APP (0.45) | APPMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6595150 | 0.81 | CTSV (0.42) | APPMAPTKMT2AMEN1CTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | APP 442/4885MAPT 1575/4885SMN1; SMN2 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.